-
Something wrong with this record ?
Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer
W. Voigt, C. Manegold, L. Pilz, YL. Wu, L. Müllauer, R. Pirker, M. Filipits, J. Niklinski, L. Petruzelka, H. Prosch,
Language English Country United States
Document type Journal Article, Review
- MeSH
- Biopsy methods MeSH
- Genetic Heterogeneity MeSH
- Precision Medicine methods MeSH
- Humans MeSH
- Lung Neoplasms diagnosis genetics pathology therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
PURPOSE OF REVIEW: The objective of this review is to discuss the strength and limitations of tissue and liquid biopsy and functional imaging to capture spatial and temporal tumor heterogeneity either alone or as part of a diagnostic framework in non-small cell lung cancer (NSCLC). RECENT FINDINGS: NSCLC displays genetic and phenotypic heterogeneity - a detailed knowledge of which is crucial to personalize treatment. Tissue biopsy often lacks spatial and temporal resolution. Thus, NSCLC needs to be characterized by complementary diagnostic methods to resolve heterogeneity. Liquid biopsy offers detection of tumor biomarkers and for example, the classification and monitoring of EGFR mutations in NSCLC. It allows repeated sampling, and therefore, appears promising to address temporal aspects of tumor heterogeneity. Functional imaging methods and emerging image analytic tools, such as radiomics capture temporal and spatial heterogeneity. Further standardization of radiomics is required to allow introduction into clinical routine. SUMMARY: To augment the potential of precision therapy, improved diagnostic characterization of tumors is pivotal. We suggest a comprehensive diagnostic framework combining tissue and liquid biopsy and functional imaging to address the known aspects of spatial and temporal tumor heterogeneity on the example of NSCLC. We envision how this framework might be implemented in clinical practice.
Department of Biomedical Imaging and Image Guided Therapy Medical University of Vienna Austria
Department of Clinical Molecular Biology Medical University of Bialystok Poland
Department of Medicine Medical University of Vienna Austria
Department of Pathology Medical University of Vienna Austria
Guangdong Lung Cancer Institute Guangdong General Hospital Guangzhou China
Institute of Cancer Research Department of Medicine 1 Medical University of Vienna Austria
Medical Faculty Mannheim University of Heidelberg Heidelberg Germany
Medical Innovations and Management Steinbeis University Berlin Berlin Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025299
- 003
- CZ-PrNML
- 005
- 20201222155141.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/CCO.0000000000000598 $2 doi
- 035 __
- $a (PubMed)31714259
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Voigt, Wieland $u Medical Innovations and Management, Steinbeis University Berlin, Berlin, Germany.
- 245 10
- $a Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer / $c W. Voigt, C. Manegold, L. Pilz, YL. Wu, L. Müllauer, R. Pirker, M. Filipits, J. Niklinski, L. Petruzelka, H. Prosch,
- 520 9_
- $a PURPOSE OF REVIEW: The objective of this review is to discuss the strength and limitations of tissue and liquid biopsy and functional imaging to capture spatial and temporal tumor heterogeneity either alone or as part of a diagnostic framework in non-small cell lung cancer (NSCLC). RECENT FINDINGS: NSCLC displays genetic and phenotypic heterogeneity - a detailed knowledge of which is crucial to personalize treatment. Tissue biopsy often lacks spatial and temporal resolution. Thus, NSCLC needs to be characterized by complementary diagnostic methods to resolve heterogeneity. Liquid biopsy offers detection of tumor biomarkers and for example, the classification and monitoring of EGFR mutations in NSCLC. It allows repeated sampling, and therefore, appears promising to address temporal aspects of tumor heterogeneity. Functional imaging methods and emerging image analytic tools, such as radiomics capture temporal and spatial heterogeneity. Further standardization of radiomics is required to allow introduction into clinical routine. SUMMARY: To augment the potential of precision therapy, improved diagnostic characterization of tumors is pivotal. We suggest a comprehensive diagnostic framework combining tissue and liquid biopsy and functional imaging to address the known aspects of spatial and temporal tumor heterogeneity on the example of NSCLC. We envision how this framework might be implemented in clinical practice.
- 650 _2
- $a biopsie $x metody $7 D001706
- 650 _2
- $a genetická heterogenita $7 D018740
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory plic $x diagnóza $x genetika $x patologie $x terapie $7 D008175
- 650 _2
- $a individualizovaná medicína $x metody $7 D057285
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Manegold, Christian $u Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Pilz, Lothar $u Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Wu, Yi-Long $u Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China.
- 700 1_
- $a Müllauer, Leonard $u Department of Pathology, Medical University of Vienna, Austria.
- 700 1_
- $a Pirker, Robert $u Department of Medicine, Medical University of Vienna, Austria.
- 700 1_
- $a Filipits, Martin $u Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Austria.
- 700 1_
- $a Niklinski, Jacek $u Department of Clinical Molecular Biology, Medical University of Bialystok, Poland.
- 700 1_
- $a Petruzelka, Lubos $u Department of Oncology, First Faculty of Medicine Charles University Prague and General University Hospital Prague, Czech Republic.
- 700 1_
- $a Prosch, Helmut $u Department of Biomedical Imaging and Image-Guided Therapy Medical University of Vienna, Austria.
- 773 0_
- $w MED00001292 $t Current opinion in oncology $x 1531-703X $g Roč. 32, č. 1 (2020), s. 68-77
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31714259 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155137 $b ABA008
- 999 __
- $a ok $b bmc $g 1599444 $s 1115985
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 32 $c 1 $d 68-77 $e - $i 1531-703X $m Current opinion in oncology $n Curr. Opin. Oncol. $x MED00001292
- LZP __
- $a Pubmed-20201125